Hint mode is switched on Switch off

Esperion Therapeutics, ordinary share
ESPR, US29664W1053

Add a stock to WL
Choose all Reset all
Esperion Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
  • Issuer
  • Full borrower / issuer name
    Esperion Therapeutics, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ESPR
  • Placement
    26.06.2013
  • Lock up period
    180
  • Number of papers
    5,000,000
  • Volume of raised funds
    70 mln USD
  • Final placement price
    14 USD
  • Price change since placement date
    -100%
  • By capitalization
    197.11 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ESPR
  • Placement
    16.10.2014
  • Lock up period
    180
  • Number of papers
    4,250,000
  • Volume of raised funds
    85 mln USD
  • Placement share
    21.58%
  • Final placement price
    20 USD
  • Price change since placement date
    -100%
  • By capitalization
    393.9 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ESPR
  • Placement
    19.03.2015
  • Lock up period
    180
  • Number of papers
    1,750,000
  • Volume of raised funds
    175 mln USD
  • Placement share
    7.89%
  • Final placement price
    100 USD
  • Price change since placement date
    -100%
  • By capitalization
    2,217.59 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ESPR
  • Placement
    10.08.2017
  • Lock up period
    180
  • Number of papers
    3,100,000
  • Volume of raised funds
    151.9 mln USD
  • Placement share
    12.07%
  • Final placement price
    49 USD
  • Price change since placement date
    -100%
  • By capitalization
    1,258.96 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ESPR
  • Placement
    22.01.2024
  • Lock up period
    180
  • Number of papers
    170,830,645
  • Volume of raised funds
    85.05 mln USD
  • Placement share
    33.19%
  • Final placement price
    1.5 USD
  • Price change since placement date
    -100%
  • By capitalization
    256.25 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ESPR
  • Placement
    08.10.2025
  • Lock up period
    180
  • Number of papers
    30,000,000
  • Volume of raised funds
    75 mln USD
  • Placement share
    12.92%
  • Final placement price
    2.5 USD
  • Price change since placement date
    -100%
  • By capitalization
    580.37 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide

Indicators

News

13/07/2026 Esperion Therapeutics: Entry Into A Material Definitive Agreement, Termination Of A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Notice Of Delisting Or Failure To Satisfy A Continuing Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors; Election Of Directors, Amendments To Articles Of Incorporation Or Bylaws; Changes In Fiscal Year, Financial Statements And Exhibits
08/07/2026 Esperion Therapeutics: Submission Of Matters To A Vote Of Security Holders
02/06/2026 Esperion Therapeutics: Other Events
02/04/2026 Esperion Therapeutics: Of The Original Report To Present The Required Financial Statements And Pro Forma Financial Information Not Later Than 71 Calendar Days From The Date On Which The Original Report Was Required To Be Filed, As Permitted Under Items 9.01(a)(3) And 9.01(b)(2). Except For The Filing Of Such Financial Statements And Pro Forma Financial Information, This Amendment Does Not Otherwise Modify Or Update The Original Report, And This Amendment Should Be Read In Conjunction With The Original Report
02/03/2026 Esperion Therapeutics: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Financial Statements And Exhibits
All organization news

Domestic and international bonds of the issuer

Holders

Industry Leaders

Registration is required to get access.